JP6445046B2 - １，１’−（１，６−ジオキソ−１，６−ヘキサンジイル）ビス−ｄ−プロリンのプロドラッグ - Google Patents

１，１’−（１，６−ジオキソ−１，６−ヘキサンジイル）ビス−ｄ−プロリンのプロドラッグ Download PDF

Info

Publication number
JP6445046B2
JP6445046B2 JP2016565212A JP2016565212A JP6445046B2 JP 6445046 B2 JP6445046 B2 JP 6445046B2 JP 2016565212 A JP2016565212 A JP 2016565212A JP 2016565212 A JP2016565212 A JP 2016565212A JP 6445046 B2 JP6445046 B2 JP 6445046B2
Authority
JP
Japan
Prior art keywords
sap
compound
disease
formula
amyloidosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016565212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514829A (ja
JP2017514829A5 (enExample
Inventor
アレクシ、ドニ
オリビエ、ミルゲ
ジェローム、トゥム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2017514829A publication Critical patent/JP2017514829A/ja
Publication of JP2017514829A5 publication Critical patent/JP2017514829A5/ja
Application granted granted Critical
Publication of JP6445046B2 publication Critical patent/JP6445046B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016565212A 2014-04-29 2015-04-27 １，１’−（１，６−ジオキソ−１，６−ヘキサンジイル）ビス−ｄ−プロリンのプロドラッグ Expired - Fee Related JP6445046B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1407506.3 2014-04-29
GBGB1407506.3A GB201407506D0 (en) 2014-04-29 2014-04-29 Novel compound
PCT/EP2015/058998 WO2015165833A1 (en) 2014-04-29 2015-04-27 A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

Publications (3)

Publication Number Publication Date
JP2017514829A JP2017514829A (ja) 2017-06-08
JP2017514829A5 JP2017514829A5 (enExample) 2018-06-14
JP6445046B2 true JP6445046B2 (ja) 2018-12-26

Family

ID=50972033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565212A Expired - Fee Related JP6445046B2 (ja) 2014-04-29 2015-04-27 １，１’−（１，６−ジオキソ−１，６−ヘキサンジイル）ビス−ｄ−プロリンのプロドラッグ

Country Status (26)

Country Link
US (3) US9701668B2 (enExample)
EP (1) EP3137457B1 (enExample)
JP (1) JP6445046B2 (enExample)
KR (1) KR20160145617A (enExample)
CN (1) CN106459016B (enExample)
AR (1) AR100204A1 (enExample)
AU (1) AU2015252184B2 (enExample)
BR (1) BR112016025129A2 (enExample)
CA (1) CA2947060C (enExample)
CL (1) CL2016002721A1 (enExample)
CR (1) CR20160508A (enExample)
DO (1) DOP2016000292A (enExample)
EA (1) EA032129B1 (enExample)
ES (1) ES2731253T3 (enExample)
GB (1) GB201407506D0 (enExample)
IL (2) IL248249A0 (enExample)
MA (1) MA39406B1 (enExample)
MX (1) MX2016014246A (enExample)
MY (1) MY191088A (enExample)
PE (1) PE20161558A1 (enExample)
PH (1) PH12016502006B1 (enExample)
SG (1) SG11201608371RA (enExample)
TW (1) TWI676624B (enExample)
UA (1) UA119871C2 (enExample)
UY (1) UY36098A (enExample)
WO (1) WO2015165833A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201518950D0 (en) 2015-10-27 2015-12-09 Glaxosmithkline Ip Dev Ltd Compound
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT915088E (pt) 1997-10-31 2003-01-31 Hoffmann La Roche Derivados de d-prolina
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
EP1636240A1 (en) 2003-06-05 2006-03-22 Pfizer Products Inc. Beta-lactamase inhibitor prodrug
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
EP1870412A4 (en) 2005-04-12 2009-12-30 Meiji Seika Kaisha 2-THIOETHENYLCARBAPENEM DERIVATIVE
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Also Published As

Publication number Publication date
TW201625598A (zh) 2016-07-16
EP3137457A1 (en) 2017-03-08
BR112016025129A2 (pt) 2017-08-15
PH12016502006A1 (en) 2016-12-19
IL279120A (en) 2021-01-31
IL248249A0 (en) 2016-11-30
AR100204A1 (es) 2016-09-21
US20180099955A1 (en) 2018-04-12
CA2947060C (en) 2023-09-26
SG11201608371RA (en) 2016-11-29
WO2015165833A1 (en) 2015-11-05
UA119871C2 (uk) 2019-08-27
US20170267665A1 (en) 2017-09-21
JP2017514829A (ja) 2017-06-08
ES2731253T3 (es) 2019-11-14
DOP2016000292A (es) 2017-11-15
PE20161558A1 (es) 2017-01-06
AU2015252184B2 (en) 2017-11-02
US9873686B2 (en) 2018-01-23
UY36098A (es) 2015-11-30
EP3137457B1 (en) 2019-04-17
US20160075694A1 (en) 2016-03-17
US10597385B2 (en) 2020-03-24
TWI676624B (zh) 2019-11-11
MX2016014246A (es) 2017-02-06
AU2015252184A1 (en) 2016-10-27
EA032129B1 (ru) 2019-04-30
EA201692185A1 (ru) 2017-06-30
CR20160508A (es) 2017-03-10
US9701668B2 (en) 2017-07-11
GB201407506D0 (en) 2014-06-11
MY191088A (en) 2022-05-30
KR20160145617A (ko) 2016-12-20
MA39406B1 (fr) 2018-04-30
CN106459016B (zh) 2019-11-01
CN106459016A (zh) 2017-02-22
PH12016502006B1 (en) 2016-12-19
MA39406A1 (fr) 2017-07-31
CL2016002721A1 (es) 2017-01-20
CA2947060A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
JP7691928B2 (ja) キナーゼ阻害剤
AU2019253831B2 (en) Compositions and methods for treating neurodegenerative diseases
US9737505B2 (en) Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
JP6445046B2 (ja) １，１’−（１，６−ジオキソ−１，６−ヘキサンジイル）ビス−ｄ−プロリンのプロドラッグ
US20240208940A1 (en) Small-molecule inhibitors for beta-catenin/bcell lymphoma 9 protein-protein interaction
JP7053762B2 (ja) Ｓａｐ枯渇剤としてのｄ－プロリン誘導体
EP3883935A1 (en) Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180427

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180427

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180530

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181128

R150 Certificate of patent or registration of utility model

Ref document number: 6445046

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees